Fig. 4
From: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
![Fig. 4](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13195-020-00678-3/MediaObjects/13195_2020_678_Fig4_HTML.png)
18F-FDG-PET measured changes of cerebral glucose metabolism (baseline – follow-up) in several AD related brain regions, revealing an improvement or slower decline in the 900-mg group than in the placebo group. p values displayed in the graph are not corrected for multiple comparison, and none survived multiple comparison correction